Clinical Trials

Title   [1031505-3] A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU)
Description   This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, and multicenter study to evaluate the efficacy of rovalpituzumab tesirine as maintenance therapy following first-line platinum-based chemotherapy.
IRB Number   17-081
Treatment   Oncology - Lung Cancer
Status   Active
Principal Name   Moh'd Khushman, M.D.
Contact Name   Kathleen Ollis

Email Newsletters

Connect With Us